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Abstract
Background: Transmission of highly pathogenic avian H5N1 viruses from poultry to humans have raised fears of an
impending influenza pandemic. Concerted efforts are underway to prepare effective vaccines and therapies including
polyclonal or monoclonal antibodies against H5N1. Current efforts are hampered by the paucity of information on
protective immune responses against avian influenza. Characterizing the B cell responses in convalescent individuals could
help in the design of future vaccines and therapeutics.
Methods and Findings: To address this need, we generated whole-genome–fragment phage display libraries (GFPDL)
expressing fragments of 15–350 amino acids covering all the proteins of A/Vietnam/1203/2004 (H5N1). These GFPDL were
used to analyze neutralizing human monoclonal antibodies and sera of five individuals who had recovered from H5N1
infection. This approach led to the mapping of two broadly neutralizing human monoclonal antibodies with conformation-
dependent epitopes. In H5N1 convalescent sera, we have identified several potentially protective H5N1-specific human
antibody epitopes in H5 HA[(-10)-223], neuraminidase catalytic site, and M2 ectodomain. In addition, for the first time to our
knowledge in humans, we identified strong reactivity against PB1-F2, a putative virulence factor, following H5N1 infection.
Importantly, novel epitopes were identified, which were recognized by H5N1-convalescent sera but did not react with sera
from control individuals (H5N1 naı ¨ve, H1N1 or H3N2 seropositive).
Conclusion: This is the first study, to our knowledge, describing the complete antibody repertoire following H5N1 infection.
Collectively, these data will contribute to rational vaccine design and new H5N1-specific serodiagnostic surveillance tools.
Please see later in the article for the Editors’ Summary.
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The recent spread of highly pathogenic (HP) H5N1 avian
influenza viruses (AIV) among poultry and transmission of these
viruses to humans raised concerns of a potential influenza
pandemic. In preparation for such an event, world-wide efforts
are under way to test and stockpile preventive vaccines, antiviral
drugs, and passive immune therapies [1,2].
Such efforts could be greatly enhanced by understanding the
immune responses of individualswho survived H5N1virus infection.
Recently, human monoclonal antibodies (MAbs) were generated
from patients in Vietnam and Turkey who had recovered from
H5N1 infections [3,4]. Some of the human MAbs demonstrated
cross-clade neutralization invitroand protected micefrom challenge
with lethal H5N1 viruses. The potential benefit of antibody therapy
was suggested during the Spanish influenza outbreak when
transfusion of convalescent sera reduced mortality by .50% [5],
and ina patient infectedwithanH5N1(clade2.3) virusinChina[6].
However, there are significant gaps in our knowledge of
antibody epitopes against H5N1 viruses, especially in humans,
and only a few epitopes have been identified in proteins other than
the haemagglutinin (HA) [7]. Characterizing the B cell responses
in convalescent individuals could help in the design of future
vaccines and therapeutics. Finally, identification of long-lasting
antibodies against conserved epitopes could assist in the develop-
ment of serological assays for surveillance of AIV infections.
To address these gaps we have constructed whole-genome–
fragment phage display libraries (GFPDL) expressing all the open
reading frames of H5N1 A/Vietnam/1203/2004. The H5N1
GFPDL were used to identify recognition sites of antibodies in
convalescent sera obtained from five Vietnamese individuals with
a history of H5N1 infection and two H5-specific neutralizing
MAbs derived from two of these survivors.
Materials and Methods
Plasma Samples and MAbs
Serum samples from five patients who survived H5N1 infection
in Vietnam were obtained at one time point within 2–6 mo
following H5N1 infection in 2004 and were previously described
(Viet-1, 24-year-old male; Viet-2, 8-year-old female; Viet-3 25-
year-old female; Viet-4, 26-year-old female; Viet-5, 23-year-old
male) [8]. MAbs FLA5.10, and FLD21.140 were derived from two
of these donors and were previously described [3]. Plasma samples
from 20 Vietnamese adults (all females, aged 20–39 y) and resident
in Vietnam but with no history of H5N1 exposure were used as
controls in antibody binding experiments. In microneutralization
assays using A/Wisconsin/67/05 (H3N2), A/New York/55/04
(H3N2), A/New Caledonia/22/99 (H1N1), and A/Solomon
Islands/03/06 (H1N1), 75% of these plasma had neutralizing
antibodies against either H3N2 strains, H1N1 strains, or both,
with titers ranging between 1:40 to 1:1,280. Ten plasma samples
from US residents with culture confirmed human seasonal
influenza infections who had high HI titers against both H1N1
and H3N2 strains circulation during the 2004–2007 seasons were
used as additional controls (no possible H5N1 exposure). All
samples were de-identified. All protocols were evaluated by the
CBER/NIH Research Involving Human Subjects Committee and
were conducted under RIHSC exemption number 03-118B.
Construction of H5N1 Gene-Fragmented Phage Display
Libraries
cDNA corresponding to all eight gene segments of the A/
H5N1/Vietnam/1203/2004 were generated from RNA isolated
from egg-grown virus strain, and were used for cloning. fSK-9-3 is
a gIIIp display-based phage vector where the desired polypeptide
can be expressed as gIIIp fusion protein.
Phage display libraries were constructed individually for HA
and neuraminidase (NA) genes (referred to as HA-NA) and the rest
of the six gene segments (PB2, PB1, PA, NP, M, and NS), referred
to as FLU-6. Purified DNA containing equimolar ratio of HA and
NA (HA-NA) or of the six genes (FLU-6) were digested with
DNase shotgun cleavage kit (Novagen) per manufacturer’s
instructions, to obtain DNA fragments in the size range of 50–
200 and 200–1,000 bp for each of the two gene segment pools.
Detailed methodology for library construction was described
previously [9].
Four libraries were constructed: fSK9-3 H5Viet-HA-NA (50–
200 bp), fSK9-3 H5Viet-HA-NA (200–1,000 bp), fSK9-3 H5Viet-
FLU-6 (50–200 bp), and fSK9-3 H5Viet-FLU-6 (200–1,000 bp)
(Figure S2).
Random Peptide Library
A random linear dodecapeptide phage display library (Ph.D-
12), wherein the displayed peptides (12-mer) are expressed fused to
the N terminus of gIII protein was purchased from New England
Biolabs.
Affinity Selection of H5N1 GFPDL Phages with MAb or
Polyclonal Human Sera
Prior to panning of GFPDL with plate-bound polyclonal serum
antibodies, serum components, which could nonspecifically
interact with phage proteins, were removed by incubation with
UV-killed M13K07 phage-coated Petri dishes. Subsequent
GFPDL affinity selection was carried out on antibody-coated
wells as well as in-solution (with Protein A/G).
For in-solution panning, 10
10 phages (of the Influenza H5
GFPDL) in 500 ml PBST containing 1% BSA were preincubated
with 200 ml of 50% Ultralink Protein A/G slurry (Pierce) for 1 h at
room temperature (RT) on end-to-end shaker. Following brief
centrifugation, 500 ml of supernatant was removed and was added
to 5 mg of human anti-H5N1 MAb or 100 ml of VCSM13-
preadsorbed human serum (in 1% BSA-PBST), and incubated for
1 h at RT on end-to-end shaker, followed by 200 ml of 50%
Ultralink Protein A/G slurry (Pierce) on end-to-end shaker at RT
for 1 h. The unbound phages were removed in ten washes with
PBST followed by three washes with PBS. The bound phages were
eluted by addition of 800 ml of 0.1 N HCl (adjusted to pH 2.2 with
glycine and BSA), and incubated for 10 min at RT on end-to-end
shaker. The eluates were collected and neutralized by adding
64 ml of 2 M Tris solution. Panning on coated strips has been
detailed in [9]. The inserts were PCR amplified and sequenced.
Peptide ELISA
Biotinylated peptides (1 mg/well) were captured onto wells
coated with 500 ng of streptavidin. After blocking with PBST
containing 2% milk, serial dilutions of human serum in blocking
solution were added to each well, incubated for 1 h at RT,
followed by addition of 2,000-fold dilution of HRP-conjugated
goat anti-human IgG-Fc specific antibody, and developed by
100 ml of OPD substrate solution. Absorbance was measured at
490–492 nm. As negative controls, peptides derived from HIV
and human CCR5 were used.
Affinity Measurements by Surface Plasmon Resonance
Steady-state equilibrium binding of MAb FLA5.10, and
FLD21.140 was monitored at 25uC using a ProteOn surface
Epitope Profile in H5N1 Survivors
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223]-His6 was coupled to a GLC sensor chip using amine
coupling with 40 resonance units (RU) in the test flow cells.
S a m p l e so f6 0 ml of freshly prepared antibody at various
concentrations were injected at a flow rate of 30 ml/min (120-s
contact time). Flow was directed over a mock surface to which no
protein was bound, followed by the HA [(-10)-223]-His6 coupled
surface. Responses from the peptide surface were corrected for
the response from the mock surface and for responses from a
separate, buffer only, injection. MAb 2D7 (anti-CCR5) was used
as a negative control antibody in various binding experiments.
Binding Kinetics for the MAbs and the data analysis was
performed using BioRad ProteON manager software (version
2.0.1). Affinity measurements were calculated using the Langmuir
with Mass transfer algorithm.
Adsorption of Polyclonal Human Sera on H5N1 GFPDL
Phages and Residual Reactivity to H5N1-Vietnam HA
Prior to panning of GFPDL, 500 ml of 10-fold diluted pooled
serum antibodies from H5N1 survivors were adsorbed by
incubation with H5N1 (HA+NA) GFPDL phage-coated Petri
dishes. To ascertain the residual antibodies specificity, an ELISA
was performed with wells coated with 200 ng/100 mlo f
recombinant H5 HA (A/Vietnam/1203/2004, Protein Scienc-
es). After blocking with PBST containing 2% milk, serial
dilutions of human serum (with or without adsorption) in
blocking solution were added to each well, incubated for 1 h at
RT, followed by addition of 2,000-fold diluted HRP-conjugated
goat anti-human IgG-Fc specific antibody and developed by
100 ml of OPD substrate solution. Absorbance was measured at
490–492 nm.
Neutralizing Antibodies Adsorption with HA1 peptides
Five-fold diluted immune serum (from sheep or ferret) (500 ml)
was added to 0.5 mg of purified HA [(-10)-223]-His6 (or shorter
HA1-derived peptides) or to control GST-His6 protein, and
incubated for 1 h at RT. Ni-NTA Sepharose beads (200 ml;
Qiagen) were added for 20 min at RT on end-to-end shaker, to
capture the His-tagged peptides and the antibodies bound to them,
followed by a brief centrifugation. Supernatants containing the
unbound antibodies were collected. The pelleted beads were
washed five times with PBST, followed by two washes with PBS.
Sepharose-peptide–bound antibodies were eluted by incubating
beads with 500 ml of 0.1 N HCl (adjusted to [pH 2.2] with glycine
and BSA), for 10 min at RT on end-to-end shaker. The eluates
were collected and neutralized by adding 40 ml of 2 M Tris
solution. In some cases, the serum adsorption was performed using
biotinylated peptides, which were captured using streptavidin-
coupled magnetic beads.
Neutralization Assay
Viral-neutralizing activity was analyzed in a microneutralization
assay on the basis of the methods of the pandemic influenza
reference laboratories of the US Centers for Disease Control
(CDC) [10–12]. The sheep anti-H5N1 A/Vietnam/1203/2004
(CBER SRID reagent), and sera from ferrets infected with wild-
type H5N1 A/Vietnam/1203/2004, were treated with a Receptor
Destroying Enzyme (RDE) overnight followed by heat-inactiva-
tion. Low pathogenicity H5N1 viruses, generated by reverse
genetics, were obtained from St. Jude, CDC, and NIBSC: A/
Vietnam/1203/2004 (SJCRH, clade 1), A/Indo/5/2005 (PR8-
IBCDC-RG2; clade 2.1), A/turkey/Turkey/1/05 (NIBRG-23;
clade 2.2), A/Anhui/1/05 (IBCDC-RG5, clade 2.3.4).
Results
Epitope Mapping of H5N1-Neutralizing MAbs
Following the outbreak of H5N1 AIV in humans in Vietnam
(2004–2005), in which 13/18 patients died [8,13], memory B cells
from peripheral blood mononuclear cells of four surviving
patients were immortalized with Epstein-Barr virus to generate
human MAbs [3]. Two of the human MAbs exhibited distinct
patterns of reactivity with clade 1 and clade 2 H5N1 viruses.
FLA5.10 had a narrow (clade 1-specific) neutralization range
(Figure 1A) and protected mice from lethal challenge with clade 1
but not clade II viruses [3]. In contrast, FLD21.140 demonstrated
broader cross-clade neutralization in vitro with very high
neutralization titers against A/Vietnam/1203/2004 (clade 1)
and A/Turkey/turkey/1/05 (clade 2.2), and a low neutralization
titer against A/Anhui/1/05 (clade 2.3.4) (Figure 1A). Interest-
ingly, although this MAb did not neutralize A/Indonesia/5/05
(clade 2.1) in vitro, it protected BALB/c mice from lethal
challenge with A/Indonesia/5/05 as previously reported [3]. We
predicted that these MAbs have different binding sites, and the
epitope of MAb FLD21.140 could be a potential target for cross-
reactive H5N1 vaccines.
Epitope mapping was addressed following the construction of
GFPDL, spanning the genome of A/Vietnam/1203/2004 (H5N1)
(Figure S1). The insert sizes in the separately constructed HA+NA
and FLU-6 libraries ranged between 50–200 bp and 200–1,000 bp
to allow presentation of conformation-dependent epitopes. The
four influenza GFPDL consisted of 9.6610
6 to 2.6610
7 phages
(Figure S2A). PCR analysis of 192 transformants per library
confirmed that the size and distribution of inserts was random
across all eight genes (Figure S2B).
Using MAb FLA5.10 for panning of the H5N1 HA+NA
libraries, multiple phages expressing an HA segment correspond-
ing to amino acids (aa) [(-10)-223] were selected that included part
of the receptor binding site (RBS) preceded by an N-terminal
sequence (Figure 1B). This HA segment contains 13 aa differences
between A/Vietnam/1203/2004 and A/Indonesia/5/05 viruses,
any of which could contribute to the clade-restricted binding of
this MAb. To delineate the specific contact residues of FLA5.10,
we used a random peptide phage display library (RPL), as
previously used to map conformation-dependent MAbs [14]. Most
of the selected phages displayed a peptide with the consensus
sequence [(H/Q)-I-(T/I)-P-X-X-X-E-(A/V)-T-L, where ‘‘X’’ is
any amino acid]. This epitope sequence mimics a nonlinear
sequence present in the RBS, which aligns with 115-QIIP-118 and
126-EASL-129 (Figure 1B, circled in red). Comparison of this
portion of the HA sequence of A/Vietnam/1203/2004 and A/
Indonesia/5/05 shows only one amino acid difference (L129S).
Direct binding of FLA5.10 to a chemically synthesized peptide
(5.10-101) and a mutated version of the peptide (5.10-101-L/A)
confirmed that L129 is a critical contact residue (Figure S3).
Importantly, these aa clusters aligned closely on the outer face of
the HA globular head on the 3-D structure of HA and are not
expected to be masked by glycosylated residues (shown in blue)
(Figure 1C).
GFPDL panning with MAb FLD21.40 identified a large
segment (HA 32–320) including the entire RBS. Subsequent
panning with RPL narrowed the putative epitope to two aa
clusters, 121-SWS-123 and 164-YNNT-167, which were separat-
ed by 40 aa in the linear sequence (Figure 1D, circled in red), but
were closely located on the 3-D structure of HA monomer
(Figure 1E). Importantly, the sequences identified are highly
conserved among clade 1 and clade 2 H5N1 viruses (including
clades 2.1, 2.2, 2.3.1, 2.3.2, 2.3.3, 2.3.4, 2.4, and 2.5) as well as
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PLoS Medicine | www.plosmedicine.org 3 April 2009 | Volume 6 | Issue 4 | e1000049Figure 1. Epitope mapping of broadly neutralizing H5N1 human MAbs. (A) End-point titers (mean of three replicates) using two H5N1
human MAbs (at 1 mg/ml) in a microneutralization assay performed with rgH5N16PR8 (2:6) reassorted viruses are shown. *, The information on in
vivo protection of mice against wild-type A/Vietnam/1203/2004 and A/Indonesia/5/05 challenge was previously published [3]. (B) HA segment [(-10)-
233] was identified by GFPDL panning using MAb FLA5.10 (boxed). Amino acid number +1 corresponds to H3 (A/California/7/2004) amino acid -10.
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PLoS Medicine | www.plosmedicine.org 4 April 2009 | Volume 6 | Issue 4 | e1000049clades 5, 6, and 8. This conservation may explain the broader
cross-neutralization in vitro and cross-protection in vivo conferred
by FLD21.140 (Figure 1A).
Binding of Human MAbs to HA Segment
To confirm that the HA segments identified using influenza
GFPDL can be recognized by neutralizing human MAbs
independent of phage presentation, the H5 HA [(-10)-223]
peptide was expressed and purified from Escherichia coli. This
protein fragment captured on a biosensor chip was used to
determine the binding kinetics of FLA5.10 (Figure 2B) and
FLD21.140 (Figure 2A). Surprisingly, FLD21.140 bound to this
HA segment with 50-fold higher affinity than FLA5.10 (Kd of 0.68
nM versus 34 nM, respectively). Such a difference in binding
affinities may predict higher avidity of binding to virus in vivo for
FLD21.140, and could contribute to its ability to protect mice
against clade 2 viruses. Therefore, both specificity and avidity
could be factors in heterologous protection.
Antibody Epitopes in the HA and NA Recognized by Sera
from Survivors of H5N1 Infection
The successful use of the GFPDL/RPL in elucidating the
conformation-dependent epitopes of two human MAbs provided
proof of concept for this approach. Next, it was important to
establish if such antibodies are represented in the polyclonal sera of
individuals who had recovered from H5N1 virus infection, and to
identify other antibody specificities that may have contributed to
virus clearance.
Convalescent sera from five H5N1 patients, obtained between
54 and 182 d following hospital admission, were analyzed using
the A/Vietnam/1203/2004 GFPDL. We first demonstrated the
capacity of the GFPDL to adsorb, at a minimum, 85% of HA-
specific antibodies in the pooled convalescent sera, as determined
by binding to recombinant H5 HA (A/Vietnam/1203/2004,
Protein Sciences) in ELISA (Figure S4), confirming the rationale of
using this approach to dissect the antibody repertoires in
polyclonal sera.
Using the HA+NA GFPDL, the pooled convalescent sera
recognized a large number of clones in the HA1, HA2, and NA
proteins (Figure 3A). The sequences and frequencies of all the
peptides that were bound by the pooled sera are presented in
Table S1. The most frequently recognized segments (numbered in
Figure 3A) were chemically synthesized or expressed in E. coli and
used in ELISA with individual convalescent sera (Viet 1-5,
Figure 3B). All five individual sera reacted with the panel of
peptides from HA1, HA2, and NA proteins. The strongest
reactivity was observed for the large HA1 peptides 1 and 2
encompassing the RBS, which were also recognized by the human
MAbs (unpublished data), and against the shorter peptides 7 and 8
in the C terminus of HA1. Phage clones expressing HA2
sequences were isolated at high frequency (Table S1), and
individual binding titers for these peptides were confirmed by
ELISA (Figure 3B, peptides 9–14). The predominant HA sites
recognized by the convalescent sera could be grouped into six
antigenic clusters (I–VI) that mapped to the outer face of the HA
trimer (Figures 3B and 4A). The HA antigenic clusters were
defined on the basis of sequences of the repeatedly selected phage
displayed epitopes (Table S1) and the confirmatory ELISA
reactivity profiles with the patients’ plasma (Figure 3B). Cluster-
I, 2,359–2,453; cluster-II: 2,454–2,621; cluster-III: 2,627–2,670;
cluster-IV: 2,682–2,703; cluster-V: 2,706–2,814; cluster-VI:
2,823–2,816. Clusters-I and -II encompass the previously
described HA1 antigenic sites ‘‘a–e’’ that were defined primarily
using mouse monoclonal antibodies against H3 influenza strains
[15,16].
Although the serum samples were obtained at a single time
point postinfection in each patient, a general pattern was observed.
The ELISA titers of Viet-5 serum (6 mo postinfection) were lower
than for earlier convalescence sera (Figure 3B). Interestingly, high
antibody titers against peptide 14 in the HA2 C terminus (HA-
2838–2866) were detected in all five samples.
To control for the potentially confounding influence of cross-
reactive antibodies elicited by seasonal influenza, we also
evaluated the binding profile of sera from 20 healthy Vietnamese
adults with no epidemiological exposure to H5N1 (Figure 3B, right
column). While modest binding to peptide 1, encompassing most
Figure 2. Steady-state binding equilibrium analysis of human
MAbs to purified bacterially expressed H5 HA[(-10-223)]
fragment. Various concentrations of MAbs FLD21.140 (A) and
FLA5.10 (B) were injected simultaneously onto recombinant HA [(-10)-
223] (identified in Figure 1B) peptide, immobilized on a sensor chip
through the free amine group, and onto a blank flow cell, free of
peptide. Binding was recorded using ProteOn system surface plasmon
resonance biosensor instrument (BioRad Labs). As a control, anti-CCR5
MAb 2D7) was injected at the same concentrations on HA [(-10)-223]
coupled chip. RU, resonance units.
doi:10.1371/journal.pmed.1000049.g002
The critical contact residues for FLA5.10, identified using RPL are shown in red circles. (C) Alignment of the critical residues for MAb FLA5.10 binding
on the 3-D structure of the HA monomer (Protein Data Base [PDB] identifier 21BX) with amino acid colors corresponding to (B). The predicted
glycosylation sites (NXT/NXS) are shown in blue. (D) HA segment (32–320) identified by GFPDL-panning using MAb FLD21.140 (boxed). The putative
contact residues identified using RPL, are shown in red circles. (E) Alignment of the critical residues for MAb FLD21.140 binding on the 3-D structure
of the HA monomer (PDB Identifier 2IBX) with amino acid colors corresponding to (D). The predicted glycosylation sites (NXT/NXS) are shown in blue.
doi:10.1371/journal.pmed.1000049.g001
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PLoS Medicine | www.plosmedicine.org 5 April 2009 | Volume 6 | Issue 4 | e1000049Figure 3. Elucidation of the epitope profile in HA and NA proteins recognized by antibodies in individuals that survived H5N1
infections in Vietnam. (A) Alignment of peptides recognized by pooled sera from H5N1-infected individuals identified using H5 (HA+NA) GFPDL.
Bars with arrows represent the identified inserts in 59–39 orientation. Numbered segments represent inserts that were selected with high frequencies
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all the other peptides was very low or absent (#1:100). These
results were expanded using 10 US individuals with culture
confirmed seasonal influenza infections and high HI titers against
both H1N1 and H3N2 (Table S2). Student’s t-test analyses (two-
tailed distribution with equal variance and a degree of freedom of
13) revealed that the binding to the H5N1 HA peptides were
significantly different (p,0.05) between the H5N1 convalescent
sera and the plasma from unexposed US and Vietnamese controls
(Table S2 and unpublished data). These findings suggested that
the antigenic map of the H5 HA revealed in our study is unlikely
to have been confounded by the presence of cross-reactive
antibodies elicited by exposure to seasonal influenza.
In the NA, a large number of epitopes captured by the pooled
convalescent sera were also recognized by the individual sera
(Figure 3A and 3B, peptides 15–21). NA peptide 15, which is 178
aa long (NA 269–447), contains the primary residues required for
sialic acid binding and the catalytic activity of NA [17] as depicted
on the NA structure in Figure 4B. This sequence was recognized at
high frequency by the convalescent sera (62 clones, Table S1) and
was the only peptide sequence within NA that showed strong
reactivity with individual sera in ELISA (Figure 3B). This region is
also .85% conserved between the human and AIV N1 NAs of A/
New Caledonia/20/99 (H1N1) and A/Vietnam/1203/2004
(H5N1), respectively. Surprisingly, Vietnamese control sera bound
peptide 15 minimally (#1:100) (Figure 3B), and no reactivity was
observed with seasonal influenza infected US control sera (Table
S2).
Antibody Epitopes in the Internal Proteins of Influenza
Recognized by Sera from Survivors of H5N1 Infection
Panning of GFPDL (FLU-6) expressing inserts from the internal
viral proteins (Figure S2A) with the pooled H5N1 convalescent
sera resulted in the isolation of many clones across all proteins
(Table S1). The majority of the fragments recognized in the
internal proteins were shorter than the HA/NA epitopes
(Figure 5A). As expected, most of the selected clones were derived
from the major structural proteins M1 and NP (531 and 91 clones,
respectively, Table S1). Peptides that were recognized at high
frequencies were synthesized and tested with individual sera in
($5; Table S1). These peptides were expressed and purified from E .coli or were chemically synthesized and used in ELISA. The sequences of the
influenza encoded fragments are numbered according to the intact complete proteome (Figure S1). Peptide ID numbers are the same in (A) and (B).
(B) ELISA reactivity of sera from individual H5N1-infected patients (Viet1–5) or pooled sera from 20 healthy Vietnamese adults (75% had neutralizing
titers against either H3N2 influenza strains, H1N1 strains, or both) with H5N1 HA1 peptides (1–8), HA2 peptides (9–14), and NA peptides (15–21)
(localization indicated in Figure 4A). An initial serum dilution (1:100) was followed by serial 5-fold dilutions. End-point titers are reported. Days
postadmission represent the time of serum collection for each patient. Six antigenic clusters in HA (cluster-I, 2,359–2,453; cluster-II, 2,454–2,621;
cluster-III, 2,627–2,670; cluster-IV, 2,682–2,703; cluster-V, 2,706–2,814; cluster-VI, 2,823–2,816) recognized by the convalescent sera are shown.
doi:10.1371/journal.pmed.1000049.g003
Figure 4. Main antigenic clusters in the structures of HA and NA recognized by antibodies from H5N1 virus infected individuals. (A)
Antigenic clusters in HA, as identified in Figure 3B, are shown as surface exposed colored patches on one HA monomer within the HA trimer structure
(PDB identifier 2IBX). The antigenic clusters (I–III) in HA1 cover the Antigenic Sites a, b, c, d, and e that have been described in the H3 HA1 based on
mouse MAbs [15,22]. (B) The immunodominant conformational epitope in the NA (NA-3676-3854, peptide 15 in Figure 3B) is shown in green on the
tetrameric NA structure (PDB Identifier 2HTY) with the predicted site of bound sialic acid shown in red. Side view and bird-eye views are shown.
doi:10.1371/journal.pmed.1000049.g004
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PLoS Medicine | www.plosmedicine.org 7 April 2009 | Volume 6 | Issue 4 | e1000049Figure 5. Antibody epitopes in H5N1 internal proteins (FLU-6) recognized by pooled sera from H5N1 infected individuals. (A)
Schematic alignment of the peptides identified using GFPDL (H5N1-FLU-6) expressing all internal proteins of influenza A/Vietnam/1203/2004. The
predicted influenza encoded proteins are numbered according to the complete proteome (Figure S1). Bars with arrows indicate identified inserts in
the 59–39 orientation. Numbered segments represent high frequency clones ($5; Table S1). These peptides were expressed and purified from E. coli
or were chemically synthesized and the numbers correspond to the peptide identifiers in the ELISA assay in (B). (B) Reactivities of sera from individual
H5N1-infected patients (Viet 1–5) or sera from healthy Vietnamese adults against peptides derived from: PB2 (1); PB1 (2–3); PB1-F2 (4–7); PA (8); NP
(9–12); M1 (13–16); M2e (17); M2 (18); NS1 (19–20); and NS2 (21).
doi:10.1371/journal.pmed.1000049.g005
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remained at high mean end-point titers (1:2,500). Control
Vietnamese pooled sera reacted weakly with peptides 10 (NP)
and 14–15 (M1). The US control sera reacted strongly with M1
peptides 13–16, reflecting the high degree of conservation in these
proteins between seasonal human influenza and H5N1 viruses [7].
As indicated before, student’s t-test analyses (two-tailed distribution
with equal variance and a degree of freedom of 13) revealed that
the ELISA reactivities against most of the H5N1 peptides were
significantly different (p,0.05) between the convalescent sera and
the plasma from unexposed US and Vietnamese controls, with the
exception of binding to selected peptides derived from PA, NP,
and M1 (p.0.05 are shown in bold in Table S2, and unpublished
data).
The M2 ectodomain (M2e) was postulated to contribute to
protective immune responses [18], but evidence for anti-M2e
responses in humans is lacking. In our study, a strong reactivity
against the M2e peptide (17) was found in H5N1 convalescent sera
but not with control sera from either Vietnam or the US
(Figure 5B; Table S2).
PB1-F2 is a 90-aa protein encoded by the PB1 gene. It was
identified as a potential virulence factor in the 1918 pandemic
H1N1 strain, and in the HP H5N1 (HK/97) viruses [19].
However, evidence for expression of this protein during human
infection is lacking. Importantly, the pooled H5N1 convalescent
sera selected 35 PB1-F2 phage clones (Table S1), and the synthetic
PB1-F2 peptides were recognized by each individual convalescent
serum, but not by the Vietnamese or US control sera (Figure 5B,
peptides 4–7; Table S2). This is the first report of antibodies
against PB1-F2 in H5N1-recovered individuals, and strongly
suggests that PB1-F2 is expressed during infection with H5N1
viruses.
HA [(-10)-223] Can Adsorb Virus-Neutralizing Activity in
Polyclonal Sera
To evaluate the functional significance of the main HA
epitopes identified using GFPDL, we evaluated the ability of the
HA peptide [(-10)-223] (that bound strongly to the H5N1-
neutralizing MAbs, FLA5.10 and FLD21.140) to block viral
neutralization using hyperimmune sheep sera raised against the
reassortant A/Vietnam/1203/046PR8 virus that had a titer of
1:640 in a microneutralization assay using the rgA/Vietnam/
1203/2004 virus (Table 1). After incubation with HA [(-10)-
223], the unbound antibody fraction lost neutralizing activity
(titer ,1:40), while the antibodies eluted from the resin-bound
HA protein retained neutralizing activity (Table 1, top panel).
Incubating the anti-H5N1 sheep serum with GST-His6 did not
adsorb any neutralizing activity. Additionally, none of the
shorter peptides within the HA [(-10)-223], alone or in
combination, adsorbed any neutralizing activity. Similar results
were obtained with sera from ferrets infected with wild-type A/
Vietnam/1203/2004 (H5N1) virus (obtained from Ruben Donis,
CDC) (Table 1, lower panel). These results demonstrate for the
first time that an HA-1 peptide, expressed in bacteria, can
adsorb the majority of anti-H5N1 neutralizing antibodies
generated in two animal species, suggesting that although most
neutralizing epitopes are conformation dependent, proper
folding and presentation of such epitopes is not necessarily
dependent on post-translational modifications restricted to
eukaryotic cells.
Discussion
GFPDL are a powerful tool to decipher all the primary
antigenic sites in influenza viruses following natural exposure or
vaccination. Previously, this approach led to the development of
HIV-SELECTEST for differential diagnosis of HIV infections in
vaccine recipients [9,20]. In the current study, we used H5N1
GFPDL to identify recognition sites of antibodies in convalescent
sera obtained from five Vietnamese individuals with a history of
H5N1 infection and two H5-specific neutralizing MAbs derived
from two of these survivors. The study identified antibodies
targeting the HA, NA, and the M2e among other proteins.
Furthermore we provide evidence that the PB1-F2, a putative viral
virulence factor, was recognized by antibodies in all five
convalescent sera of H5N1-infected individuals (mean end-point
titers of $1:500).
Table 1. Adsorption of neutralization activity using HA peptides.
Sera Peptides Added Titer
Sheep anti-A/Vietnam/1203/04 sera No peptide 640
HA [(-10)-223]-FLOW-THROUGH ,40
HA [(-10)-223]-ELUATE 640
GST-His-FLOW-THROUGH 640
GST-His-ELUATE ,40
HA 35-96+HA 99-121 FLOW-THROUGH 640
HA 120-149+HA 185-206 FLOW-THROUGH 640
HA 491-534 FLOW-THROUGH 640
Ferret anti-A/Vietnam/1203/04-infected sera (2004-53) No peptide 640
HA [(-10)-223] FLOW-THROUGH ,40
HA 35-96+HA 99-121 FLOW-THROUGH 640
HA 120-149+HA 185-206 FLOW-THROUGH 640
HA 491-534 FLOW-THROUGH 640
HA [(-10)-223] can adsorb most of the neutralizing activity in polyclonal sera. Sera from sheep hyperimmunized with bromelain-treated rgA/Vietnam/1203/2004 (FDA),
or from ferrets infected with wild-type A/Vietnam/1203/2004 virus (CDC) were adsorbed on different H5 HA peptides and subjected to a microneutralization assay
performed with rgA/Vietnam/1203/2004 virus. End-point neutralization titers of various pre- or postadsorbed sera are shown.
doi:10.1371/journal.pmed.1000049.t001
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binding sites on the structures of human influenza HA [15,16,21–
23], and more recently, of H5 HA [24,25]. In contrast, until
recently, very limited information was available on human
antibody epitopes in type A viruses, and even less for avian
H5N1 viruses [7].
Elucidating the repertoire of influenza-specific human antibod-
ies against all the viral proteins is desired for understanding virus-
host interactions and identifying new targets for protection. To
that end, we used influenza GFPDL to unravel the antibody
specificities of five H5N1-recovered individuals and to map the
epitopes of two neutralizing MAbs derived from their memory B
cells. Our main findings were: (1) H5N1 convalescent sera
contained highly diverse antibody specificities against HA1,
HA2, NA, and internal proteins of the virus for at least 6 mo;
(2) two human MAbs, which were protective in mice, recognized
conformation-dependent nonlinear epitopes in large HA1 frag-
ments that encompass the RBS; (3) the HA1[(-10)-223)] protein
showed high avidity binding to the two human MAbs and
adsorbed a significant proportion of the neutralizing activity of
polyclonal anti-H5N1 sheep and ferret sera; (4) strong antibody
reactivity against the NA catalytic site and M2e were identified; (5)
convalescent sera bound PB1-F2 peptides providing evidence that
this protein is expressed during acute H5N1 infection; (6) sera
from 20 Vietnamese adults with no history of H5N1 infection, and
from ten US human influenza-confirmed infections, revealed very
low reactivity to most of the H5N1 epitopes.
Deciphering the epitopes of the H5-specific human MAbs
explained the restricted neutralization pattern of FLA5.10
compared with FLD21.140. MAb FLA5.10 binding requires
L129, a critical amino acid within the RBS. A L129S change was
reported in clade 2 H5N1 viruses from China and Southeast Asia
in 2002–2005 [26], and could explain the clade 1-restricted
protection provided by FLA5.10. Preliminary data from escape
mutants (ALS and KS) support the FLA5.10 epitope identified by
phage display libraries (unpublished data). On the other hand, the
predicted contact residues for FLD21.140 are highly conserved
among clade 1 and clade 2 H5N1 viruses and the high binding
affinity of this MAb for the HA [(-10)-223)] fragment may explain
its broad cross-protection in vivo. Importantly, for both MAbs the
combined GFPDL/RPL approach identified noncontinuous
conformation dependent epitopes.
Panning of GFPDL (HA+NA) with sera from individuals who
had recovered from H5N1 virus infection revealed broad antibody
reactivity against both HA1 and HA2 domains, including the large
HA1 fragments bound by the protective human MAbs. Epitope
profiling of HA led to identification of six antigenic clusters (I–VI).
HA antigenic sites ‘‘a–e’’ were defined primarily using mouse
monoclonal antibodies that are encompassed in clusters-I and -II,
described in this study.
A recent paper by Throsby et al., describes heterosubtypic
neutralizing MAbs that cross react against H5N1 and H1N1 [27].
The epitopes of these monoclonal antibodies were mapped to
amino acids 43–58 in HA2. This sequence corresponds to H5-HA-
2723-2378 in our study, and was part of several peptide sequences
displayed on the affinity selected phage clones (Figure 3B, peptides
10–12; Table S1). While all five H5N1 recovered individuals had
titers against these HA2 peptides (reciprocal titers 500–2,500),
binding of control plasma (from Vietnam or the US) to these
peptides was observed at low frequency, and the titers did not
exceed 1:100 (Figure 3B; Table S2).
Among the H5N1 convalescent plasma, most ELISA reciprocal
titers were lower in the 6-mo postinfection sample. However, HA2
peptide (H5-HA-2838-2866) located in the membrane proximal
domain was strongly recognized by all convalescent sera
(Figure 3B), but did not bind control sera from Vietnam or from
US individuals with recent culture-confirmed seasonal influenza
infections. This highly conserved HA2 region contains aa changes
between H5, H1, and H3 viruses [28] and could be useful for
surveillance of H5N1 infections in endemic areas.
This study also identified a strong binding by the H5N1
convalescent sera to a 178-aa fragment containing the NA
catalytic site that has not been reported previously. This NA
segment was not recognized by US control sera with high HI titers
against H1N1. Therefore, we did not find evidence that repeated
exposure to human H1N1 influenza viruses elicits high-titer
antibodies against the heterologous avian N1 NA, as was
previously predicted [29].
Studies in mice have shown that serum anti-M2e antibodies can
reduce virus replication and death. Currently, M2 is being
evaluated as a component of several ‘‘universal vaccines’’[30–33],
and possibly as target for monoclonal antibody therapies [32,34].
However, the immunogenicity of M2e during natural influenza
infections is still debated [35]. Surprisingly, the GFPDL analyses
revealed high titer anti-M2e antibodies in post-H5N1 infection sera
(but not in control sera). Although the N-terminal (1–9 aa) sequence
of M2e is highly conserved across different influenza-A subtypes,
thereis significant diversityintheC-terminal (10–21aa)sequence of
M2e (http://www.flu.lanl.gov). Also, similar GFPDL analyses using
the pooled sera from 20 control H5N1-uninfected Vietnamese
females did not select any phage-displaying peptide sequence from
the M2 region. This result suggests that strong antibody response is
generated against M2e following primary infection with HP H5N1
strain. Thus, the contribution of M2e antibodies to viral clearance
after H5N1 infection should be further evaluated.
PB1-F2, a recently discovered proapoptotic influenza-A viral
protein, contributes to viral pathogenesis in mice [36]. However,
this protein is not incorporated into viral particles, and evidence
for its expression during influenza infection of animals or humans
is lacking. In our study, 35 PB1-F2–expressing GFPDL clones
were isolated, and sera from all five H5N1 infection survivors, but
not control sera, reacted with synthetic PB1-F2 peptides in ELISA.
To our knowledge, this is the first report indicating that PB1-F2 is
expressed during H5N1 virus infection in humans. It is not clear
how this short-lived protein activates B cells. However, high viral
replication and cell lysis during H5N1 infection could present the
newly expressed viral proteins to the immune system.
The use of GFPDL to decipher the complete B cell repertoires in
AIV-exposed individuals is limited by the fact that all protein
segments are expressed in a bacterial system. Therefore, epitopes
that are strictly dependent on post-translational modifications or on
the multimeric forms of influenza proteins in the native structure
might have been missed in our analyses. In spite of these limitations,
the use of GFPDL led to new insights into the repertoire of anti-
influenza antibodies following H5N1 virus infection and of epitopes
that may contribute to resolution of avian influenza infections and
could be incorporated into future vaccines. Finally, conserved
epitopes recognized by sera from convalescent individuals may be
useful for monitoring outbreaks of avian influenza.
Supporting Information
Figure S1 The complete H5N1 A/Vietnam/1203/04 proteome
sequence was constructed by linking the 11 proteins (protein
names are shown within the proteome sequence) coded by the
eight gene segments derived from wild-type A/Vietnam/1203/
2004 viral RNA grown in embryonated chicken eggs. The
predicted glycosylation sites (NXT/NXS) in HA are underlined.
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DOC)
Figure S2 Construction of H5N1 A/Vietnam phage display
libraries: size and insert distribution. (A) Four phage display
libraries for the H5N1 strain A/Vietnam/1203/2004 were
constructed: fSK9-3 H5Viet-HA-NA (50–200-bp inserts); fSK9-3
H5Viet-HA-NA (200–1,000-bp inserts); fSK9-3 H5Viet-FLU-6
(50–200-bp inserts) (PB2, PB1, PA, NP, M, and NS genes); and
fSK9-3 H5Viet- FLU-6 PB2-NS (200–1,000-bp inserts). Each
library size was calculated by plating serial dilutions of E. coli
transformants following electroporation. (B) Sequence diversity of
inserts in complete H5N1 gene-fragment phage display library.
190 colonies from each library were subjected to PCR-based
sequencing. Representative alignment of A/Vietnam/1203/2004
genome sequence with inserts in combined (fSK9-3 H5Viet-HA-
NA [50–200 bp] and fSK9-3 H5Viet- FLU-6 PB2-NS [(50–200
bp]) gene-fragment phage display library is shown. Arrow
indicates the orientation of inserts. Similar distribution of inserts
was found for the fSK9-3 H5Viet-HA-NA (200–1,000 bp) and
fSK9-3 Viet- FLU-6 PB2-NS (200–1,000 bp). All open reading
frames of the influenza-coded proteins were represented in the
GFPDL with good representation of smaller and larger inserts in
both the transfected bacteria and the phage libraries.
Found at: doi:10.1371/journal.pmed.1000049.s002 (0.75 MB
EPS)
Figure S3 Binding of MAb FLA5.10 to peptide 5.10-101
(identified using RPL panning) compared with mutated peptide
5.10-101-L1A in ELISA. Both biotinylated peptides were captured
on streptavidin-coated plates and reacted with serial dilutions of
FLA5.10. Leucine to alanine substitution resulted in .98% loss of
FLA5.10 binding.
Found at: doi:10.1371/journal.pmed.1000049.s003 (0.37 MB
EPS)
Figure S4 Adsorption of anti-HA antibodies in convalescent sera
from survivors of H5N1 infection using the H5N1 GFPDL. Pooled
sera from five H5N1 survivors were adsorbed with H5 (HA+NA)
GFPDL. Binding to recombinant HA protein (A/Vietnam/1203/
2004, Protein Sciences Corporation) is shown before (circles) and
after (triangles) GFPDL-adsorption.
Found at: doi:10.1371/journal.pmed.1000049.s004 (0.38 MB
EPS)
Table S1 Frequency of selected phage clones using H5N1
GFPDL after panning with sera from five H5N1-Vietnam
infection survivors. Three rounds of affinity selection were
performed on pooled sera using each of the four GFPDL under
both conditions (antibody coated beads and in-solution). 48 clones
were sequenced in each panning round, resulting in sequencing of
2,304 total clones. The peptide sequences displayed on the phage
surface and the corresponding frequencies for these phage
displayed sequences are shown. Each peptide name indicates the
H5N1 protein name and the amino acid numbers corresponding
to the complete proteome sequence shown in Figure S1.
Sequences in bold letters represent peptides that were used for
synthesis and follow up binding assays.
Found at: doi:10.1371/journal.pmed.1000049.s005 (0.14 MB
DOC)
Table S2 ELISA reactivity of sera from ten individuals with
culture-confirmed seasonal influenza infections during the 2006–
2007 seasons. End-point antibody titers (based on 5-fold dilutions
starting at 1:100) are reported for US 1–10 against the identical
H5N1-Viet peptides used in Figures 4B and 6B). Student t-test was
performed for each peptide reactivity using the end-point titers for
the control sera (e.g., if end-point titer was ,100, the value used
for statistical analysis was 20), compared with the end-point titers
of the five H5N1-convelescent samples (e.g., if end-point titer was
.12,500, the value used for statistical analysis was 12,500). p-
Values appear in the right column.
Found at: doi:10.1371/journal.pmed.1000049.s006 (0.15 MB
DOC)
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Background. Every winter, millions of people catch
influenza, a viral infection of the airways. Most recover
quickly but seasonal influenza outbreaks (epidemics) kill
about half a million people annually. These epidemics occur
because small but frequent changes in the viral proteins
(antigens) to which the human immune system responds
mean that an immune response produced one year by
infection or through vaccination provides only partial
protection against influenza the next year. Influenza viruses
also occasionally appear that contain major antigenic
changes. Human populations have little or no immunity to
such viruses (which often originate in animals or birds), so
they can start deadly global epidemics (pandemics ).
Worryingly, the last influenza pandemic occurred in 1968
and many experts fear that another pandemic is now
overdue. The trigger for such a pandemic, they think, could
be the avian (bird) H5N1 influenza virus, which first appeared
in 1996 in a goose in China. The name indicates the types of
two major influenza antigens present in the virus: H5N1
carries type 5 hemagglutinin and type 1 neuraminidase.
Why Was This Study Done? H5N1 has caused about 400
confirmed cases of human influenza and more than 250
deaths in the past decade but it has not started a human
pandemic because it cannot pass easily between people.
However, it could possibly acquire this ability at any time, so
it is a priority to develop both vaccines that will provide
protection against a pandemic H5N1 viral strain, as well as
antibody-based antiviral therapies for people not protected
by vaccination (antibodies are proteins produced by the
immune system that help to fight infections; people can
sometimes be protected from infection by injecting them
with pre-prepared antibodies). To do this, scientists need to
know how the human immune system responds to the H5N1
virus. In particular, they need to know which parts of the
virus the immune system can detect and make antibodies
against. In this study, therefore, the researchers characterize
the specific antibody responses found in people recovering
from infection with H5N1.
What Did the Researchers Do and Find? The researchers
made several ‘‘genome-fragment phage display libraries’’,
collections of bacterial viruses (phages) engineered so that
each phage makes one of many possible short pieces
(polypeptides) of a nonphage protein. Such ‘‘libraries’’ can be
used to investigate which fragments are recognized by
antibodies from a given source. In this case, several libraries
were made that contained fragments of the genome of the
H5N1 strain responsible for an outbreak of human influenza
in Vietnam in 2004–2005 (A/Vietnam/1203/2004). The
researchers used these libraries to analyze the antibodies
made by five Vietnamese people recovering from infection
with A/Vietnam/1203/2004. H5N1 convalescent blood
samples, the researchers report, contained antibodies that
recognized small regions (‘‘epitopes’’) in several viral
proteins, including hemagglutinin, neuraminidase, a
structural protein called M2, and a viral protein called PB1-
F2 that is partly responsible for the severity of H5N1
infections. Several of the novel epitopes identified were
not recognized by antibodies in blood taken from people
recovering from infection with other influenza viruses. The
researchers also used their phage display libraries to analyze
two neutralizing human monoclonal antibodies generated
from patients infected with A/Vietnam/1203/2004
(neutralizing antibodies protect mice against normally
lethal challenge with H5N1; monoclonal antibodies are
generated in the laboratory by creating continuously
growing cell lines that produce a single type of antibody).
Importantly, both of the neutralizing monoclonal antibodies
recognized ‘‘noncontinuous conformation-dependent
epitopes’’—protein sequences that are not adjacent to one
another in the polypeptide sequence of the protein, but that
lie close together in space because of the way the protein is
folded up.
What Do These Findings Mean? Although some aspects
of the antibody repertoire produced in people exposed to
the H5N1 influenza virus may have been missed in this
analysis, these findings provide important and detailed new
information about how the human immune system responds
to infection with this virus. In particular, they show that
people recovering from H5N1 infection make a diverse range
of antibodies against several viral proteins for at least six
months and identify specific parts of H5N1 that may be
particularly good at stimulating a protective immune
response. This information can now be used to help design
vaccines against H5N1 and antibody-based therapies for the
treatment of H5N1 infections, and to develop new tools for
monitoring outbreaks of avian influenza in human
populations.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000049.
N This study is further discussed in a PLoS Medicine
Perspective by Malik Peiris
N The US Centers for Disease Control and Prevention
provides information for about influenza for patients and
professionals, including specific information on avian and
pandemic influenza (in several languages)
N The World Health Organization provides information on
influenza (in several languages) and on H5N1 avian
influenza (in several languages), and a global timeline
about H5N1 avian influenza infection in birds and people
N The UK Health Protection Agency provides information on
avian, pandemic, and epidemic (seasonal) influenza
N MedlinePlus provides a list of links to other information
about influenza and bird flu (in English and Spanish)
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